Therapeutic Effect Observation of Jinkui Shenqi Pill Assisted with Percutaneous Kyphoplasty on Osteoporotic Vertebral Compression Fracture

OBJECTIVE To observe the clinical effect of Jingui Shenqi pill assisted with percutaneous kyphoplasty(PKP) on osteoporotic vertebral compression fracture(OVCF). METHODS The 124 patients with OVCF from February 2015 to February 2018 were enrolled and divided into observation group and control group according to the random number table, with 62 cases in each group. The control group was treated with PKP operation and routine treatment for 3 months after operation, and on this basis, the observation group was treated with Jingui shenqi pill for 4 weeks. A one-year follow-up was conducted to observe and compare the differences of EVOS, ODI score, bone density, vertebral height, VAS and QOL-100 scores between the two groups before operation, 3 months after operation and one year after operation. The changes of bone metabolic indexes of PINP, β-CTX, BGP and BALP before and 3 months after operation were detected, and the occurrence of adverse events and re-fracture was recorded. RESULTS The EVOS scores in the observation group were higher than those in the control group at 3 months and one year after operation(P<0.05), and the ODI scores were lower(P<0.05); the height ratio of the responsible vertebrae was greater(P<0.05), and the Cobb angle was lower(P<0.05). One year after operation, the bone mineral density in the observation group was significantly higher than that before operation and 3 months after operation, and was higher than that in the control group(P<0.05). The levels of BGP in the observation group were higher than those in the control group(P<0.05), and the levels of PINP, BALP and β-CTX were lower(P<0.05). The QOL-100 scores in the observation group were higher than those in the control group at 3 months and 1 year after operation(P<0.05), and the VAS scores were lower(P<0.05). The incidence of vertebral re-fracture in the observation group was 3.23% lower than that in the control group 16.13%(χ²=4.521, P<0.05). CONCLUSION Jingui Shenqi pill assisted with PKP in the treatment of OVCF patients, the clinical effect is significant, and the recurrence rate of fracture is low, which is worthy of clinical application.